RBC Europe’s Alnylam Pharmaceuticals ALNY Stock Holding History

RBC Europe’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$729K	Hold	5,000	–	–	0.04%	121
2022 Q1	$816K	Hold	5,000	–	–	0.03%	118
2021 Q4	$848K	Buy	5,000 +855	+21%	+$159K	0.04%	120
2021 Q3	$783K	Hold	4,145	–	–	0.03%	161
2021 Q2	$703K	Sell	4,145 -4,000	-49%	-$586K	0.03%	178
2021 Q1	$1.15M	Hold	8,145	–	–	0.06%	132
2020 Q4	$1.06M	Hold	8,145	–	–	0.06%	133
2020 Q3	$1.19M	Buy	8,145 +950	+13%	+$135K	0.08%	120
2020 Q2	$1.07M	Sell	7,195 -1,000	-12%	-$135K	0.08%	120
2020 Q1	$892K	Sell	8,195 -3,565	-30%	-$412K	0.09%	108
2019 Q4	$1.35M	Hold	11,760	–	–	0.12%	100
2019 Q3	$946K	Hold	11,760	–	–	0.09%	121
2019 Q2	$853K	Buy	11,760 +2,500	+27%	+$192K	0.09%	126
2019 Q1	$865K	Buy	9,260 +500	+6%	+$41.8K	0.1%	121
2018 Q4	$639K	Buy	8,760 +1,570	+22%	+$121K	0.08%	129
2018 Q3	$629K	Buy	7,190 +5	+0.1%	+$503	0.07%	140
2018 Q2	$708K	Buy	7,185 +1,040	+17%	+$103K	0.08%	133
2018 Q1	$732K	Buy	6,145 +645	+12%	+$83.2K	0.09%	128
2017 Q4	$699K	Sell	5,500 -1,500	-21%	-$188K	0.09%	130
2017 Q3	$822K	Buy	+7,000	New	+$597K	0.11%	118

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RBC Europe's ALNY Position: Q2 2022 in Review

RBC Europe held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2022 at 5,000 shares worth $729K. The position accounts for 0.04% of the portfolio, ranked #121.

RBC Europe first reported a position in ALNY in Q3 2017 and has held it in 20 quarters since. The position peaked at $1.35M in Q4 2019. 422 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

RBC Europe held 5,000 shares of Alnylam Pharmaceuticals worth $729K as of Q2 2022.
RBC Europe left its Alnylam Pharmaceuticals share count unchanged in Q2 2022.
Alnylam Pharmaceuticals made up 0.04% of RBC Europe's portfolio in Q2 2022, its #121 holding.
RBC Europe first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 20 quarters since.
RBC Europe's Alnylam Pharmaceuticals position peaked at $1.35M in Q4 2019.
422 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.